0001019687-16-007064.txt : 20160803 0001019687-16-007064.hdr.sgml : 20160803 20160803082742 ACCESSION NUMBER: 0001019687-16-007064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160801 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160803 DATE AS OF CHANGE: 20160803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32046 FILM NUMBER: 161802295 BUSINESS ADDRESS: STREET 1: 42505 10TH STREET WEST STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-7059 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 42505 10TH STREET WEST CITY: LANCASTER STATE: CA ZIP: 93534-7059 8-K 1 simulations_8k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

August 1, 2016

(Date of the earliest event reported)

 

 

 

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

California 001-32046 95-4595609
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

42505 10th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

 

 

661-723-7723

Registrant's telephone number, including area code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01       Regulation FD Disclosure

 

On August 1, 2016, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing that its board of directors has declared a quarterly cash dividend of $0.05 per share of common stock, payable on August 18, 2016 to shareholders of record on August 11, 2016.

 

A copy of press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information contained in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

 

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This Current Report on Form 8-K may contain forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained in this Current Report or with respect to the announcements described herein.

 

 

Item 9.01       Financial Statements and Exhibits

 

(d)       Exhibits

 

99.1       Press release issued on August 1, 2016.

 

 

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  SIMULATIONS PLUS, INC.
   
Dated:August 3, 2016 By: /s/ John R. Kneisel
    John R. Kneisel
Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
EX-99.1 2 simulations_8k-ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

Aug. 1, 2016 12:30 UTC

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, August 18, 2016, to shareholders of record as of Thursday, August 11, 2016.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.05 per share per quarter. Of course, the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.

View source version on businesswire.com:
http://www.businesswire.com/news/home/20160801005507/en/

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

 

Source: Simulations Plus, Inc.

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg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end